126 results on '"Santacana, Maria"'
Search Results
2. Data from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
3. Supplementary Figure 3 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
4. Supplementary Figure 2 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
5. Supplementary Table 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
6. Data from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
7. Supplementary Figure 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
8. Supplementary Figure 3 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
9. Supplementary Figure 4 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
10. Supplementary Figure Legend from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
11. Supplementary Figure 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
12. Supplementary Figure 5 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
13. Supplementary Figure 2 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
14. Supplementary Figure 4 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
15. Supplementary Figure 5 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
16. Supplementary Table 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
17. Legends Supplementary Data from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
18. Legends Supplementary Data from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
19. Figure S1 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
20. Figure S4 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
21. Figure S2 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
22. Figure S2 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
23. Figure S1 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
24. Figure S5 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
25. Figure S5 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
26. Figure S3 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
27. Data from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
28. Figure S4 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
29. Data from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
30. Figure S3 from T-Type Cav3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma
31. Supplementary Tables 1-2 from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
32. Data from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
33. Data from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
34. Supplementary Figures 1-10 from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
35. Supplementary Figures 1-10 from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
36. Supplementary Tables 1-2 from Immune-Dependent and Independent Antitumor Activity of GM-CSF Aberrantly Expressed by Mouse and Human Colorectal Tumors
37. Oxidative stress‐induced FAK activation contributes to uterine serous carcinoma aggressiveness
38. Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer
39. Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer
40. Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function
41. ARID1A ‐deficient cells require HDAC6 for progression of endometrial carcinoma
42. Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
43. CD44-negative parietal–epithelial cell staining in minimal change disease: association with clinical features, response to corticosteroids and kidney outcome
44. BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics
45. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients
46. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
47. Private Speech in the Framework of Referential Communication
48. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study
49. Developing indicators for quality assurance in cytopathology. Catalan Society of Cytopathology
50. Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.